Literature DB >> 6223578

Concentrations of cefoperazone in cerebrospinal fluid during bacterial meningitis.

D Cable, G Overturf, G Edralin.   

Abstract

Cefoperazone was administered to 15 patients with bacterial meningitis before lumbar punctures were performed. Patients received one of the following three dosage regimens before collection of cerebrospinal fluid (CSF): one dose of 50 mg/kg (maximum, 2 g; group I), one dose of 100 mg/kg (maximum, 4 g; group II), three doses of 100 mg/kg each every 8 h (maximum, 4 g each dose; group III). Of 44 CSF samples, 26 had detectable cefoperazone levels (59%); drug concentrations in CSF ranged from less than 0.8 to 11.5 micrograms/ml (median, 1.97 micrograms/ml). Although the percentage of patients with detectable cefoperazone levels in CSF was higher in group III (69%) than in group II (64%) or group I (50%), the differences were not statistically significant; however, the mean drug concentration in CSF in group I (1.53 micrograms/ml) was significantly lower than that in group III (3.1 micrograms/ml). A high protein concentration in CSF (as an indicator of meningeal inflammation) correlated best with high cefoperazone concentrations in CSF. These findings differ from previous investigations of cefoperazone penetration into CSF; however, cefoperazone may not penetrate reliably into CSF and therefore may not be an optimal candidate drug for the treatment of bacterial meningitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223578      PMCID: PMC184788          DOI: 10.1128/AAC.23.5.688

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Meningitis due to Haemophilus influenzae type b resistant to ampicillin and chloramphenicol.

Authors:  N Uchiyama; G R Greene; D B Kitts; L D Thrupp
Journal:  J Pediatr       Date:  1980-09       Impact factor: 4.406

2.  Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis.

Authors:  S H Landesman; M L Corrado; C C Cherubin; M Gombert; D Cleri
Journal:  Am J Med       Date:  1980-07       Impact factor: 4.965

3.  Microbiological studies on cefoperazone.

Authors:  F H Kayser
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

4.  In vitro and in vivo antibacterial activity of cefoperazone.

Authors:  S Mitsuhashi; S Minami; N Matsubara; A Yotsuji; S Kurashige; I Saikawa
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

5.  Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; E H Gerlach; H M Sommers
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

6.  Meningitis due to Haemophilus influenzae type b resistant to both ampicillin and chloramphenicol.

Authors:  J F Kenny; C D Isburg; R H Michaels
Journal:  Pediatrics       Date:  1980-07       Impact factor: 7.124

7.  Intravenous cefotaxime in children with bacterial meningitis.

Authors:  B H Belohradsky; K Bruch; D Geiss; D Kafetzis; W Marget; G Peters
Journal:  Lancet       Date:  1980-01-12       Impact factor: 79.321

Review 8.  Antibiotic-resistant Streptococcus pneumoniae: clinical and epidemiologic aspects.

Authors:  J Ward
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

9.  Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis.

Authors:  S L Kaplan; E O Mason; H Garcia; S J Kvernland; E M Loiselle; D C Anderson; A A Mintz; R D Feigin
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

10.  Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.

Authors:  U B Schaad; G H McCracken; N Threlkeld; M L Thomas
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

View more
  4 in total

Review 1.  Cephalosporins in adult meningitis.

Authors:  T R Beam
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 2.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Treatment of bacterial meningitis with ceftizoxime.

Authors:  G D Overturf; D C Cable; D N Forthal; C Shikuma
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.